

CURRICULUM VITAE

Preston C. Sprenkle, MD

Version Date: 7/10/2026

Contact Information:

Address 789 Howard Avenue
Ste FMP315B
New Haven, CT 06519
Phone: 1 (203) 785-7671
Email: preston.sprenkle@yale.edu

School: Yale School of Medicine

Education:

09/1994 - 06/1998 BA, Stanford University, Human Biology, Palo Alto, CA
08/2000 - 05/2004 MD, Columbia University, New York, NY
09/2016 - 05/2018 Yale School of Management, Emerging Leaders Program, New Haven, CT

Career/Academic Appointments:

07/2004 - 06/2005 Internship, General Surgery, New York Presbyterian Hospital, New York, NY
07/2005 - 06/2009 Residency, Urology, New York Presbyterian Hospital, New York, NY
07/2009 - 12/2011 Fellowship, Urologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
09/2012 - 06/2018 Assistant Professor, Urology, Yale School of Medicine, New Haven, CT
07/2018 - 06/2030 Associate Professor on Term, Urology, Yale School of Medicine, New Haven, CT
07/2025 - 06/2030 Associate Professor on Term, Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT

Administrative Positions:

2014 - Present Director, Urology Research Fellowship, Urology, Yale School of Medicine, New Haven, CT
2014 - 2023 Director, Urologic Oncology Clinical Fellowship Program, Urology, Yale School of Medicine, New Haven, CT
2015 - Present Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System, West Haven, CT
2017 - Present Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare System, West Haven, CT

2019 - 2020	Chair, YNHH Robotics Committee, Yale New Haven Hospital, Yale New Haven Hospital, New Haven, CT
2021 - 2025	Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA
2024 - Present	Chair, Robotic Surgery Advisory Board, National Surgery Office, Washington, DC
2025 - Present	Chair, National Comprehensive Cancer Network, NCCN Prostate Cancer Early Detection Guidelines Committee, Plymouth Meeting, PA

Board Certification:

2014 - 2024	AB of Urology, Urology
-------------	------------------------

Professional Honors & Recognition:

International/National/Regional

2004	Arnold P. Gold Humanism in Medicine Honors Society
2004	Alpha Omega Alpha Medical School Honors Society
2006	First Prize - NY section AUA Valentine Essay Contest, NY Academy of Medicine
2007	Finalist - NY section AUA Valentine Essay Contest, NY Academy of Medicine
2009	Best Poster Podium Presentation, Young Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting
2009	Finalist - NY section AUA Valentine Essay Contest, NY Academy of Medicine
2025	2nd prize, Poster Competition, FOCAL+ CME

Yale University/Yale School of Medicine/Hospital System

1997	Member, Board of Directors, Stanford University Alumni Association
1998	Outstanding Member of Stanford Community, Stanford University
2017 - 2020	Mentor Appreciation Award, Interprofessional Longitudinal Clinical Experience
2021	2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine

Grants/Clinical Trials History:

Current Clinical Trials

Agencies:	National Cancer Institute (NCI)
I.D.#:	0805003787
Title:	Genitourinary Cancer Data and Specimen Repository
P.I.:	Michael Hurwitz
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	0.0000
Project period:	10/03/2008 - ongoing

Agencies:	Yale Cancer Center
I.D.#:	1501015246

Title: Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
P.I.: Preston C. Sprenkle
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 03/13/2015 - ongoing

Agencies: Yale University School of Medicine
I.D.#: 1510016603REG
Title: Focal Cryoablation of the Prostate: Tissue and Data Repository
P.I.: Preston C. Sprenkle
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 12/16/2015 - ongoing

Agencies: Eastern Coop Onc Group-American College Radiology Imaging Netwk(ECOG-ACRIN)
I.D.#: 2000024244
Title: Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
P.I.: Jeffrey Weinreb
Role: Sub-Investigator
Percent effort: N/A
Total costs: 0.0000
Project period: 11/02/2018 - ongoing

Agencies: Southwest Oncology Group (SWOG)
I.D.#: 2000025125
Title: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
P.I.: Preston C. Sprenkle
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 07/01/2019 - ongoing

Agencies: Profound Medical Inc.
I.D.#: 2000029224
Title: Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

P.I.: Sandeep Arora
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/03/2021 - ongoing

Agencies: Yale Cancer Center
 I.D.#: 2000027702
 Title: Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

P.I.: Kimberly L. Johung
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 09/20/2021 - ongoing

Agencies: Profound Medical Inc.
 I.D.#: 2000030487
 Title: Customized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)

P.I.: Sandeep Arora
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 09/28/2021 - ongoing

Agencies: Rutgers, The State University of New Jersey
 I.D.#: 2000031291
 Title: Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer

P.I.: Isaac Y. Kim
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/27/2022 - ongoing

Agencies: Yale Cancer Center
 I.D.#: 2000034160
 Title: Promoting Equity through a Culturally-Tailored Prostate Cancer Genetics Video for African American Males for Impact Long-term - PREVAIL Study

P.I.: Veda Giri
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 01/24/2023 - ongoing

Agencies: Yale Cancer Center
 I.D.#: 2000037284
 Title: PRISM: Patient Experiences with PET Imaging in Prostate Cancer
 P.I.: Michael S. Leapman
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/15/2024 - ongoing

Agencies: Yale Cancer Center
 I.D.#: 2000039076
 Title: A Phase II Study of Consolidative Local Therapy in Patients With Locally Advanced or Oligo-metastatic Urothelial Carcinoma (la/mUC) Following Treatment Response to Systemic Therapy With or Without Metastasis-directed Radiotherapy
 P.I.: Fed Ghali
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 11/03/2025 - ongoing

Agencies: Yale University School of Medicine
 I.D.#: 2000041449
 Title: Effects of High Intensity Interval Training Among Patients with Prostate Cancer Prior to Radical Prostatectomy
 P.I.: Michael S. Leapman
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 11/26/2025 - ongoing

Past Grants

Agency: Department of Defense
 I.D.#: GR109111
 Title: Combining Therapeutic Response Genomic Signatures with Machine Learning to Predict Patient Outcome from Potentially Lethal Prostate Cancer
 P.I.: Darryl T. Martin
 Role: Investigator

Percent effort: 5%
 Total costs: \$1,211,250.00
 Project period: 07/01/2020 - 06/30/2023

Agency: Bio-Imaging's Inside MRI Grant
 I.D.#: GR113836
 Title: Inside-Out Nonlinear Gradients to Improve Diffusion MRI
 P.I.: Gigi Galiana
 Role: Investigator
 Percent effort: 3%
 Total costs: \$758,649.00
 Project period: 07/06/2021 - 06/30/2026

Agency: FDA/CERSI
 I.D.#: FR117786
 Title: Yale-Mayo Clinic FDA Center of Excellence in Regulatory Science and Innovation
 P.I.: Michael S. Leapman
 Role: Investigator
 Percent effort: 2%
 Total costs: \$8,631,957.34
 Project period: 09/01/2022 - 08/31/2023

Agency: Leet-Patterson Trust
 I.D.#: GR108958
 Title: 2020 Seery Foundation Mentored Research Award for Cancer Research
 P.I.: Michael S. Leapman
 Role: Collaborator
 Percent effort: 5%
 Total costs: \$100,033.25
 Project period: 04/30/2020 - 01/31/2023

Past Clinical Trials

Agencies: Yale Cancer Center
 I.D.#: 1304011902
 Title: MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 06/24/2013 - 02/19/2026

Agencies: National Institutes of Health (NIH)
 I.D.#: 1308012586

Title: PDGFR-a, TERT Promoter Mutation and Polyamine Signaling in the Bladder Tissues
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 09/16/2013 - 09/10/2014

Agencies: Yale University School of Medicine
 I.D.#: 1310012809
 Title: MR-US Fusion Prostate Biopsy Database
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/31/2013 - 10/14/2015

Agencies: Yale University School of Medicine
 I.D.#: 1312013110
 Title: Active Surveillance of the Small Renal Mass
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/17/2014 - 02/11/2020

Agencies: Yale Cancer Center
 I.D.#: 1402013376
 Title: Prostate Cancer Screening in Men with Germline BRCA2 Mutations
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 04/09/2014 - 07/15/2019

Agencies: Yale University School of Medicine
 I.D.#: 1501015186EXEMPT
 Title: The impact of non-disease related factors on survival in patients with penile cancer
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/05/2015

Agencies: Progenics Pharmaceuticals
 I.D.#: 1511016824
 Title: A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
 P.I.: Preston C. Sprenkle
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: 0.0000
 Project period: 03/16/2016 - 05/14/2018

Agencies: Progenics Pharmaceuticals
 I.D.#: 1609018370
 Title: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
 P.I.: Lawrence Saperstein
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: 0.0000
 Project period: 11/17/2016 - 08/30/2018

Agencies: BESO Biological Research, Inc.
 I.D.#: 2000020868
 Title: Assessing the Clinical Response of Prostate Cancer to a Fermented Soy Extract
 P.I.: Michael S. Leapman
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/05/2017 - 04/27/2020

Agencies: Advanced Accelerator Applications International SA
 I.D.#: 2000023359
 Title: A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
 P.I.: Lawrence Saperstein
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/11/2018 - 07/28/2020

Agencies: Progenics Pharmaceuticals
 I.D.#: 2000024006

Title: A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

P.I.: Lawrence Saperstein

Role: Sub-Investigator

Percent effort: N/A

Total costs: -

Project period: 11/15/2018 - 01/28/2020

Agencies: Curium US LLC

I.D.#: 2000031831

Title: A Multi-Center, Open-Label, Randomized Phase 1/2 Study of Copper Cu 64 PSMA I&T Injection in Patients with Histologically Proven Metastatic Prostate Cancer

P.I.: Ming-Kai Chen

Role: Sub-Investigator

Percent effort: N/A

Total costs: -

Project period: 12/06/2022 - 12/05/2023

Agencies: Southwest Oncology Group (SWOG)

I.D.#: 2000036263

Title: Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

P.I.: Joseph Kim

Role: Sub-Investigator

Percent effort: N/A

Total costs: -

Project period: 10/30/2023 - 01/29/2026

Pending Clinical Trials

Agencies: -

I.D.#: 2000042589

Title: Urinary Biomarker Testing During Active Surveillance of Prostate Cancer

P.I.: Michael S. Leapman

Role: Sub-Investigator

Percent effort: N/A

Total costs: -

Agencies: Department of the Army

I.D.#: 2000027508

Title: Determining Genomic Signatures of Prostate Cancer to Predict Subject Outcome

P.I.: Darryl T. Martin

Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/16/2020 - ongoing

Agencies: Yale Cancer Center
 I.D.#: 2000031290
 Title: SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer

P.I.: Isaac Y. Kim
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 01/15/2022 - ongoing

Agencies: National Cancer Institute (NCI)
 I.D.#: 2000030538
 Title: Inside-Out Nonlinear Gradients to Improve Diffusion MRI
 P.I.: Gigi Galiana
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/03/2022 - ongoing

Agencies: Yale University
 I.D.#: 2000033470
 Title: Real-world outcomes of novel positron emission tomography (PET) imaging tracers for prostate cancer
 P.I.: Michael S. Leapman
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 09/06/2022 - ongoing

Agencies: National Cancer Institute (NCI)
 I.D.#: 2000035122
 Title: Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imaging
 P.I.: Michael S. Leapman
 Role: Sub-Investigator
 Percent effort: N/A

Total costs:	-
Project period:	04/20/2023 - ongoing
Agencies:	Yale University School of Medicine
I.D.#:	2000040175
Title:	Outcomes of local treatment for oligometastatic prostate cancer diagnosed using PSMA PET imaging: OLIGOMET study.
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/19/2025 - ongoing
Agencies:	Yale University School of Medicine
I.D.#:	2000040675
Title:	Active Surveillance in Intermediate Risk Prostate Cancer
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	07/24/2025 - ongoing
Agencies:	Yale University School of Medicine
I.D.#:	2000041500
Title:	Identifying Predictors of Oncologic Outcomes of Prostate Cancer Using Approaches to Pattern 4 Quantification on Prostate Biopsy
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	12/11/2025 - ongoing
Agencies:	Yale Cancer Center
I.D.#:	2000042200
Title:	Clinical Outcomes in Prostate Cancer
P.I.:	Michael S. Leapman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/23/2026 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. "Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant.". Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant.", San Francisco, CA, January 2006 - December 2006. (Other)
2. "Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer.". Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer.", Bethesda, MD, January 2009 - December 2009. (Other)
3. "Image Registration in MR-US Fusion biopsy". American Urological Association continuing education course, Image Registration in MR-US Fusion biopsy, Chicago, IL, January 2016. (Lecture)
4. "Focal ablation for prostate cancer". New England Section of AUA, Focal ablation for prostate cancer, Portland, ME, January 2016. (Oral Presentation)
5. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2017. (Oral Presentation)
6. "Principles of Image Registration". American Urological Association continuing education course, Principles of Image Registration, Linthicum Heights, MD, January 2017. (Lecture)
7. "MR-US fusion biopsy in practice: Yale University experience". American Urological Association continuing education course, MR-US fusion biopsy in practice: Yale University experience, Linthicum Heights, MD, January 2017. (Oral Presentation)
8. "Yale experience with SpaceOAR rectal spacer". New England Section of AUA, Yale experience with SpaceOAR rectal spacer, Montreal, QC, January 2017. (Oral Presentation)
9. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2018. (Oral Presentation)
10. "Hands On Training Course, MR-US fusion prostate biopsy tips and tricks". American Urological Association, Hands On Training Course, MR-US fusion prostate biopsy tips and tricks, San Francisco, CA, January 2018. (Demonstration)
11. "Hands-On demonstration of MR-US fusion prostate biopsy". American Urological Association, Hands-On demonstration of MR-US fusion prostate biopsy, Chicago, IL, January 2019. (Demonstration)
12. "Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates". AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates, Boston, MA, January 2019. (Oral Presentation)
13. "Integrating a rectal spacer procedure into urology practice". American Urological Association, Integrating a rectal spacer procedure into urology practice, Chicago, IL, January 2019. (Other)
14. "Prostate Cancer Session Moderator". New England Section of AUA, Prostate Cancer Session Moderator, Providence, RI, January 2019. (Other)
15. "Multimodal treatment of advanced prostate cancer, discussion panel member". New England Section of AUA, Multimodal treatment of advanced prostate cancer, discussion panel member, Providence, RI, January 2019. (Address)

16. "Negative prostate MRI, can prostate biopsy be avoided?". European Society of Medicine Congress 2021, Negative prostate MRI, can prostate biopsy be avoided?, Vienna, Vienna, January 2021. (Lecture)
17. "Update on NCCN Early Detection of Prostate Cancer Guidelines". AdMeTech Foundation, 5th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, Boston, MA, September 2021. (Oral Presentation)
18. "Negative Multiparametric MRI of the Prostate: can biopsy be avoided?". European Society of Medicine, European Society of Medicine Annual Congress, Vienna, Vienna, November 2021. (Lecture)
19. "Molecular Diagnostics in the VA". VHA National Surgery Office, Prostate Cancer Diagnosis Symposium, Department of Veterans Affairs, National Surgery Office, February 2023. (Oral Presentation)
20. "Update on NCCN guidelines for Prostate Cancer Early Detection". AdMeTech Foundation, 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, International Summit Hosted by AdMeTech, September 2023. (Lecture)
21. "Margin Call: focal vs regional ablation for prostate cancer". FOCAL CME, FOCAL CME 2023, Chicago, IL, November 2023. (Lecture)
22. "Advancements in Prostate Cancer Screening and Diagnosis". Profound Medical, PRO-Talk Live, Las Vegas, NV, September 2024. (Oral Presentation)
23. "Update on NCCN Early Detection of Prostate Cancer Guidelines". ADMETECH 8th Global Summit, International conference featuring speakers from around the world., October 2024. (Oral Presentation)
24. "Advances in prostate cancer screening". Profound Medical, PRO-Talk Live, Las Vegas, NV, September 2025. (Oral Presentation)
25. "Update on changes to NCCN Prostate Cancer Early Detection Guidelines". ADMETECH foundation, ADMETECH 9th Global Summit, World Summit with international attendance and speakers, September 2025. (Oral Presentation)
26. "Role of MRI in prostate cancer diagnosis and ablation therapy". Profound Medical Inc., ProTalk Live, Bogotá, DC, April 2026. (Lecture)
27. "Image-guided therapies utilizing MRI". Yale-Siemens collaborative meeting, Erlangen, BY, April 2026. (Lecture)
28. "Biomarkers and Advanced Imaging to Inform Screening Practice". American Urological Association Annual Meeting, Washington, DC, May 2026. (Lecture)
29. "Smarter Prostate Cancer Screening". American Urological Association Annual Meeting, Washington, DC, May 2026. (Oral Presentation)
30. "Prostate Cancer Focal Therapy for Veterans". United States Association of Urologic Surgeons for Veterans, American Urological Association Annual Meeting, Washington, DC, May 2026. (Oral Presentation)
31. "Focus on: ADT in the modern Era-Balancing Cancer control and Cardiovascular Safety". American Urological Association Annual Meeting, Washington, DC, May 2026. (Oral Presentation)
32. "Yale Experience with TULSA Pro and CAPTAIN Trial Update". International Society of Therapeutic Ultrasound, Trondheim, Trøndelag, June 2026. (Oral Presentation)

Regional

1. "Grand Round Presentation "Management of T1 Bladder Cancer". Grand Round Presentation "Management of T1 Bladder Cancer", Brooklyn, NY, January 2011 - December 2011. (Other)
2. "Emerging role of MR-US fusion prostate biopsy". Connecticut Urological Association, Emerging role of MR-US fusion prostate biopsy, Hartford, CT, January 2015. (Oral Presentation)
3. "MR-US Fusion prostate biopsy: improving prostate cancer diagnosis". Association of Operating Room Nurses, MR-US Fusion prostate biopsy: improving prostate cancer diagnosis, West Haven, CT, January 2015. (Oral Presentation)
4. "Prostate Cancer Screening". SCAN-ECHO regional educational conference, Prostate Cancer Screening, West Haven, CT, January 2015. (Oral Presentation)
5. "Session Moderator: Prostate cancer genomics panel". New England Section of AUA, Session Moderator: Prostate cancer genomics panel, Hartford, CT, January 2018. (Address)
6. "Prostate Biopsy: Transrectal vs Transperineal approach". New England Section of the American Urological Association, New England Section of American Urological Association Annual Meeting, Portland, ME, September 2022. (Oral Presentation)
7. "Moderator, Scientific Session VII". New England Section of the American Urological Association, Providence, RI, September 2024. (Other)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. The bladder trigone is not a Wolffian duct remnant. American Urological Association, The bladder trigone is not a Wolffian duct remnant, San Francisco, CA, January 2006. (Oral Presentation)
2. B7x is a serum marker for prostate cancer. Society of Urological Oncology Annual meeting, B7x is a serum marker for prostate cancer, Bethesda, MD, January 2009. (Oral Presentation)
3. Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients. Society of Urologic Oncology, Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients, Bethesda, MD, January 2012. (Oral Presentation)
4. MRI-US fusion prostate biopsy, improving cancer detection. New England Section AUA, MRI-US fusion prostate biopsy, improving cancer detection, Providence, RI, January 2014. (Oral Presentation)
5. MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis.. New England Section of AUA, MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis., Nassau, New Providence, January 2015. (Oral Presentation)
6. MRI-Fusion biopsy in a first-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale.. American Urological Association, MRI-Fusion biopsy in a first-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale., Orlando, FL, January 2015. (Oral Presentation)
7. Should we still biopsy patients with a negative MP-MRI?. American Urological Association Annual Meeting, Should we still biopsy patients with a negative MP-MRI?, San Diego, CA, January 2016. (Oral Presentation)

8. MR-US Fusion Biopsy, West Haven VA experience. American Urological Association, MR-US Fusion Biopsy, West Haven VA experience, Boston, MA, January 2017. (Oral Presentation)
9. Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance. AdMeTech foundation Global Summit on Precision Diagnosis for Prostate Cancer, Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance, Boston, MA, January 2017. (Oral Presentation)
10. Physician learning curve using MR-US fusion prostate biopsy. New England Section of AUA, Physician learning curve using MR-US fusion prostate biopsy, Montreal, QC, January 2017. (Oral Presentation)

Professional Service:

Peer Review Groups/Grant Study Sections

2014 - 2021	Board Member, NCCN Prostate Cancer Early Detection Guideline Panel
2019	Ad-hoc reviewer, NIH, Ad Hoc reviewer for NIH Clinical Trials Genitourinary Steering Committee
2021 - Present	Grant Reviewer, Prostate Cancer UK, Review Prostate Cancer UK grants for consideration for funding. typically 2-3 grants/year
2021 - Present	Member, VHA National Surgery Office - Robotic Surgery Surgical Advisory Board
2021 - Present	Grant Reviewer, Prostate Cancer UK
2021 - 2025	Vice Chair, NCCN Prostate Cancer Early Detection Guideline Panel
2023 - Present	Thesis Reviewer, PhD candidate Thesis examiner - Joanna Chen
2025 - Present	Chair, NCCN Early Detection of Prostate Cancer Guidelines
2026	Judge, USAV annual Meeting Podium Presentation review committee, Reviewed and judged oral abstract presentation competition

Advisory Boards

2019 - Present	Advisor, Scientific Advisory Board, Boston Scientific Inc., Scientific review and advice on urologic products
2021 - 2024	Member, Robotics Committee, Surgical Advisory Board, National Surgery Office
2022 - Present	Board Member, Clinical Advisory Board, Profound Medical
2022 - Present	Advisor, Scientific Advisory Board, Telix Pharmaceuticals
2024 - Present	Advisor, Scientific Advisory Board, Johnson & Johnson
2024 - 2027	Chair, Robotics Surgical Advisory Board, National Surgery Office
2025 - Present	Committee Member, Executive Committee, Connecticut Urological Society
2025	Board Member, Clinical Advisory Board, Wren Laboratories
2025 - Present	Board Member, Clinical Advisory Board, Insight Medbotics
2025 - Present	Scientific Advisor, Scientific Advisory Board, Angiodynamics Inc

Journal Services

Editorial boards

2015 - Present	Associate Editor, Frontiers
----------------	-----------------------------

Reviewer

2009 - Present	Reviewer, Journal of Urology
2009 - Present	Reviewer, Frontiers in Science
2009 - Present	Reviewer, Urology
2015 - Present	Reviewer, Clinical Genitourinary Cancer
2015 - Present	Reviewer, PLOS One
2016 - Present	Reviewer, Urologic Oncology
2016 - Present	Reviewer, Oncotarget
2016 - Present	Reviewer, Nature Scientific Reports
2021 - Present	Reviewer, European Urology

Professional Organizations

American Association of Clinical Urologists

2006 - Present	Member, American Association of Clinical Urologists
----------------	---

Society of Urologic Oncology

2009 - Present	Member, Society of Urologic Oncology
----------------	--------------------------------------

Yale Interdisciplinary Prostate Program

2015 - Present	Founding Member, Yale Interdisciplinary Prostate Program, Interdisciplinary group focused on collaborative research and development of clinical programs in prostate cancer
----------------	---

Yale University / Hospital System

Medical School

2021 - 2023	Member, Department of Urology Medical Student Thesis review committee
-------------	---

Department

2015 - 2019	Member, Department of Urology Residency Promotion Committee
2016 - Present	Member, Department of Urology Executive Committee
2024 - Present	Member, Diversity, Equity, and Inclusion Committee

Hospital

2014 - 2016	Member, Urologic Clinical Cost and Value Committee
2014 - 2016	Expert Panel Member, Interventional Radiology Purchasing Committee
2018 - Present	Representative, MCIC LLC, Surgeon representative on multi-institutional meetings to improve clinical outcomes
2020 - 2021	Chair, Robotic Credentialing and Privileging committee, Multidisciplinary committee to review and define acceptable requirements to attain and maintain robotic surgery privileges.
2021 - Present	Member, YNHH Robotic Surgery Committee

Public Service / Media Presence

Public Service

2008	Participant, Washington Heights free prostate cancer education and screening clinic
2015 - Present	Participant, Yale Urology Prostate Cancer Screening Clinic

Bibliography:

Peer-Reviewed Original Research

1. Batourina E, Tsai S, Lambert S, **Sprenkle P**, Viana R, Dutta S, Hensle T, Wang F, Niederreither K, McMahon AP, Carroll TJ, Mendelsohn CL. Apoptosis induced by vitamin A signaling is crucial for connecting the ureters to the bladder. *Nature Genetics* 2005, 37: 1082-1089. [PMID: 16186816](#), [DOI: 10.1038/ng1645](#).
2. **Sprenkle P**, Lowe F. Benign prostate hyperplasia in the older male. *Aging Health* 2007, 3: 177-189. [DOI: 10.2217/1745509x.3.2.177](#).
3. Pierorazio PM, Lambert SM, Matsukhani M, **Sprenkle PC**, McCann TR, Katz AE, Olsson CA, Benson MC, McKiernan JM. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. *BJU International* 2007, 100: 1066-1070. [PMID: 17784880](#), [DOI: 10.1111/j.1464-410x.2007.07115.x](#).
4. Pierorazio P, Lambert S, Matsukhani M, **Sprenkle P**, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. *BJU International* 2007, 0: 070907021207002-???. [DOI: 10.1111/j.1464-410x.2007.07115.x](#).
5. Hruby GW, **Sprenkle PC**, Abdelshehid C, Clayman RV, McDougall EM, Landman J. The EZ Trainer: Validation of a Portable and Inexpensive Simulator for Training Basic Laparoscopic Skills. *Journal Of Urology* 2007, 179: 662-666. [PMID: 18082210](#), [DOI: 10.1016/j.juro.2007.09.030](#).
6. Durak E, Hruby GW, Okhunov Z, **Sprenkle P**, Mirabile G, Marruffo F, Landman J. Complete Ileal Neobladder Intracorporeal Construction With Standard Sutured Technique and Novel Technology. *Journal Of Urology* 2010, 183: 1227-1231. [PMID: 20096862](#), [DOI: 10.1016/j.juro.2009.11.005](#).
7. **Sprenkle PC**, Mirabile G, Durak E, Edelstein A, Gupta M, Hruby GW, Okhunov Z, Landman J. The Effect of Argon Gas Pressure on Ice Ball Size and Rate of Formation. *Journal Of Endourology* 2010, 24: 1503-1507. [PMID: 20649444](#), [DOI: 10.1089/end.2009.0587](#).
8. Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, **Sprenkle P**, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. *Journal Of Urology* 2010, 185: 37-42. [PMID: 21074196](#), [PMCID: PMC3437930](#), [DOI: 10.1016/j.juro.2010.08.084](#).
9. **Sprenkle P**, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? *Journal Of Medicine And The Person* 2011, 9: 116-122. [DOI: 10.1007/s12682-011-0101-y](#).
10. **Sprenkle PC**, Power N, Ghoneim T, Touijer KA, Dalbagni G, Russo P, Coleman JA. Comparison of Open and Minimally Invasive Partial Nephrectomy for Renal Tumors 4–7 Centimeters. *European*

- Urology 2011, 61: 593-599. [PMID: 22154728](#), [PMCID: PMC6693652](#), [DOI: 10.1016/j.eururo.2011.11.040](#).
11. **Sprenkle PC**, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, Sternberg I, Fleisher M, Russo P. Urine Neutrophil Gelatinase-Associated Lipocalin as a Marker of Acute Kidney Injury After Kidney Surgery. Journal Of Urology 2013, 190: 159-164. [PMID: 23391468](#), [PMCID: PMC4167359](#), [DOI: 10.1016/j.juro.2013.01.101](#).
 12. Silberstein JL, **Sprenkle PC**, Su D, Power NE, Tarin TV, Ezell P, Sjoberg DD, Feifer A, Fleisher M, Russo P, Touijer KA. Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model. BJU International 2013, 112: 517-525. [PMID: 23510358](#), [PMCID: PMC4235973](#), [DOI: 10.1111/bju.12066](#).
 13. Ehrenberg H, Cornfeld D, Nawaf C, **Sprenkle P**, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2016, 9785: 97851j-97851j-14. [DOI: 10.1117/12.2216904](#).
 14. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaildone MC, Sonn G, **Sprenkle P**, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines® Insights Prostate Cancer Early Detection, Version 2.2016. Journal Of The National Comprehensive Cancer Network 2016, 14: 509-519. [PMID: 27160230](#), [PMCID: PMC10184498](#), [DOI: 10.6004/jnccn.2016.0060](#).
 15. Nguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, **Sprenkle P**. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report. Journal Of Clinical Urology 2016, 10: 280-282. [DOI: 10.1177/2051415816651561](#).
 16. MacKintosh FR, **Sprenkle PC**, Walter LC, Rawson L, Karnes RJ, Morrell CH, Kattan MW, Nawaf CB, Neville TB. Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Frontiers In Oncology 2016, 6: 157. [PMID: 27446803](#), [PMCID: PMC4923265](#), [DOI: 10.3389/fonc.2016.00157](#).
 17. Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, **Sprenkle PC**. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. [PMID: 28322902](#), [DOI: 10.1016/j.urology.2017.01.048](#).
 18. Onofrey JA, Staib LH, Sarkar S, Venkataraman R, Nawaf CB, **Sprenkle PC**, Papademetris X. Learning Non-rigid Deformations for Robust, Constrained Point-based Registration in Image-Guided MR-TRUS Prostate Intervention. Medical Image Analysis 2017, 39: 29-43. [PMID: 28431275](#), [PMCID: PMC5514316](#), [DOI: 10.1016/j.media.2017.04.001](#).
 19. Syed JS, Nguyen KA, Nawaf CB, Bhagat AM, Huber S, Levi A, Humphrey P, Weinreb JC, Schulam PG, **Sprenkle PC**. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion. Urologic Oncology Seminars And Original Investigations 2017, 35: 542.e19-542.e24. [PMID: 28501565](#), [DOI: 10.1016/j.urolonc.2017.04.011](#).
 20. Sheridan AD, Nath SK, Syed JS, Aneja S, **Sprenkle PC**, Weinreb JC, Spektor M. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI. American Journal Of Roentgenology 2017, 210: 347-357. [PMID: 29112469](#), [DOI: 10.2214/ajr.17.18516](#).

21. Sheridan AD, Nath SK, Aneja S, Syed JS, Pahade J, Mathur M, **Sprenkle P**, Weinreb JC, Spektor M. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. American Journal Of Roentgenology 2018, 210: w218-w225. [PMID: 29489409](#), [DOI: 10.2214/ajr.17.18680](#).
22. Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, **Sprenkle PC**, Kattan MW, Colicchia M, Neville TB. Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort. Frontiers In Oncology 2018, 8: 296. [PMID: 30128303](#), [PMCID: PMC6088151](#), [DOI: 10.3389/fonc.2018.00296](#).
23. Martin DT, Ghabili K, Levi A, Humphrey PA, **Sprenkle PC**. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. [PMID: 30552940](#), [DOI: 10.1016/j.urology.2018.12.001](#).
24. Onofrey JA, Casetti-Dinescu DI, Lauritzen AD, Sarkar S, Venkataraman R, Fan RE, Sonn GA, **Sprenkle PC**, Staib LH, Papademetris X. Generalizable Multi-Site Training and Testing Of Deep Neural Networks Using Image Normalization. 2011 IEEE International Symposium On Biomedical Imaging: From Nano To Macro 2019, 00: 348-351. [PMID: 32874427](#), [PMCID: PMC7457546](#), [DOI: 10.1109/isbi.2019.8759295](#).
25. Lu AJ, Syed JS, Ghabili K, Hsiang WR, Nguyen KA, Leapman MS, **Sprenkle PC**. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. European Urology 2019, 76: 14-17. [PMID: 31047733](#), [DOI: 10.1016/j.eururo.2019.04.008](#).
26. Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, **Sprenkle PC**. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance. European Urology Focus 2019, 7: 47-54. [PMID: 31147263](#), [DOI: 10.1016/j.euf.2019.05.011](#).
27. Ghabili K, Swallow M, Sherrer RL, Syed JS, Khajir G, Gordetsky JB, Leapman MS, Rais-Bahrami S, **Sprenkle PC**. Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4. Urology 2019, 134: 173-180. [PMID: 31419433](#), [DOI: 10.1016/j.urology.2019.08.008](#).
28. Grinberg AS, Sellinger J, **Sprenkle PC**, Bandin AJ, Nawaf CB, Syed JS, Leapman MS. Effect of Diaphragmatic Breathing on Procedural Anxiety During Transrectal Prostate Biopsy. Urology 2019, 137: 26-32. [PMID: 31893532](#), [DOI: 10.1016/j.urology.2019.12.024](#).
29. Ghabili K, Park HS, Yu JB, **Sprenkle PC**, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. [PMID: 32562045](#), [DOI: 10.1007/s00345-020-03298-6](#).
30. Syed J, **Sprenkle P**. Benign and Malignant Diseases of the Prostate. 2020, 651-682. [DOI: 10.1007/978-3-319-47771-8_79](#).
31. Yang DX, Verma V, An Y, Yu JB, **Sprenkle PC**, Leapman MS, Park HS. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances In Radiation Oncology 2020, 5: 1225-1231. [PMID: 33305083](#), [PMCID: PMC7718530](#), [DOI: 10.1016/j.adro.2020.08.015](#).

32. Torres R, Olson E, Homer R, Martin DT, Levene MJ, Perincheri S, **Sprenkle PC**, Humphrey PA. Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology. Archives Of Pathology & Laboratory Medicine 2020, 145: 583-591. [PMID: 32991670](#), [DOI: 10.5858/arpa.2020-0037-oa](#).
33. Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, **Sprenkle PC**. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. [PMID: 33936831](#), [PMCID: PMC8054861](#), [DOI: 10.1155/2021/2687416](#).
34. Paulson N, Vollmer RT, Humphrey PA, **Sprenkle PC**, Onofrey J, Huber S, Amirkhiz K, Levi AW. Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. Archives Of Pathology & Laboratory Medicine 2021, 146: 201-204. [PMID: 34015819](#), [DOI: 10.5858/arpa.2020-0568-oa](#).
35. Wibmer AG, Kattan MW, Alessandrino F, Baur ADJ, Boesen L, Franco FB, Bonekamp D, Campa R, Cash H, Catalá V, Crouzet S, Dinnoo S, Eastham J, Fennessy FM, Ghabili K, Hohenfellner M, Levi AW, Ji X, Løgager V, Margolis DJ, Moldovan PC, Panebianco V, Penzkofer T, Puech P, Radtke JP, Rouvière O, Schlemmer HP, **Sprenkle PC**, Tempany CM, Vilanova JC, Weinreb J, Hricak H, Shukla-Dave A. International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer. Cancers 2021, 13: 2627. [PMID: 34071842](#), [PMCID: PMC8198352](#), [DOI: 10.3390/cancers13112627](#).
36. Press BH, Khajir G, Ghabili K, Leung C, Fan RE, Wang NN, Leapman MS, Sonn GA, **Sprenkle PC**. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology 2021, 155: 96-100. [PMID: 34087311](#), [DOI: 10.1016/j.urology.2021.05.035](#).
37. Wang NN, Zhou SR, Chen L, Tibshirani R, Fan RE, Ghanouni P, Thong AE, To'o KJ, Ghabili K, Nix JW, Gordetsky JB, **Sprenkle P**, Rais-Bahrami S, Sonn GA. The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 831.e19-831.e27. [PMID: 34247909](#), [DOI: 10.1016/j.urolonc.2021.06.004](#).
38. Leapman MS, Wang R, Park HS, Yu JB, **Sprenkle PC**, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. [PMID: 34623406](#), [PMCID: PMC8501394](#), [DOI: 10.1001/jamanetworkopen.2021.28646](#).
39. Martin DT, Lee JS, Liu Q, Galiana G, **Sprenkle PC**, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. [PMID: 34740868](#), [DOI: 10.1016/j.nano.2021.102477](#).
40. Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, **Sprenkle P**, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. [PMID: 37145694](#), [DOI: 10.1097/upj.0000000000000290](#).
41. Leapman MS, Wang R, Park H, Yu JB, **Sprenkle PC**, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. [PMID: 34762100](#), [PMCID: PMC8587214](#), [DOI: 10.1001/jamaoncol.2021.5143](#).

42. Press BH, Jones T, Olawoyin O, Lokeshwar SD, Rahman SN, Khajir G, Lin DW, Cooperberg MR, Loeb S, Darst BF, Zheng Y, Chen RC, Witte JS, Seibert TM, Catalona WJ, Leapman MS, **Sprenkle PC**. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. *European Urology Open Science* 2022, 37: 113-119. [PMID: 35243396](#), [PMCID: PMC8883188](#), [DOI: 10.1016/j.euros.2022.01.008](#).
43. Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, **Sprenkle PC**. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. *Urologic Oncology Seminars And Original Investigations* 2022, 40: 407.e21-407.e27. [PMID: 35811206](#), [DOI: 10.1016/j.urolonc.2022.06.005](#).
44. Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana-Prakash N, Vourganti S, Filson CP, Sonn GA, **Sprenkle PC**, Gupta GN, Punnen S, Rais-Bahrami S. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. *Cancer* 2022, 128: 3287-3296. [PMID: 35819253](#), [DOI: 10.1002/cncr.34355](#).
45. Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, **Sprenkle PC**, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. *JCO Clinical Cancer Informatics* 2022, 6: e2200016. [PMID: 36179281](#), [DOI: 10.1200/cci.22.00016](#).
46. Moses K, **Sprenkle P**, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. *Journal Of The National Comprehensive Cancer Network* 2023, 21: 236-246. [PMID: 36898362](#), [DOI: 10.6004/jnccn.2023.0014](#).
47. Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, **Sprenkle P**, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. *JNCI Cancer Spectrum* 2023, 7: pkad099. [PMID: 38085220](#), [PMCID: PMC10733209](#), [DOI: 10.1093/jncics/pkad099](#).
48. Khajir G, Sun T, Wang H, **Sprenkle P**, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up. *Cytopathology* 2023, 35: 235-241. [PMID: 37916579](#), [DOI: 10.1111/cyt.13328](#).
49. Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolzco J, Washington S, Renzulli J, **Sprenkle P**, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. *Urologic Oncology Seminars And Original Investigations* 2023, 42: 28.e9-28.e20. [PMID: 38161105](#), [DOI: 10.1016/j.urolonc.2023.10.005](#).
50. Kim I, Wang A, Corpuz G, **Sprenkle P**, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. *Prostate International* 2024, 12: 70-78. [PMID: 39036758](#), [PMCID: PMC11255894](#), [DOI: 10.1016/j.pnil.2024.01.002](#).
51. Zeevi T, Leapman M, **Sprenkle P**, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. *IEEE*

- Transactions On Biomedical Engineering 2024, 71: 1084-1091. [PMID: 37874731](#), [PMCID: PMC10901528](#), [DOI: 10.1109/tbme.2023.3326799](#).
52. Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, **Sprenkle P**. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. [PMID: 38874922](#), [PMCID: PMC11179136](#), [DOI: 10.1001/jamanetworkopen.2024.17274](#).
 53. Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, **Sprenkle P**, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy. Urology 2024, 193: 87-94. [PMID: 39019332](#), [DOI: 10.1016/j.urology.2024.07.014](#).
 54. Sundaresan V, Wang R, Long J, **Sprenkle P**, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. [PMID: 39196719](#), [PMCID: PMC12400587](#), [DOI: 10.1097/upj.0000000000000679](#).
 55. Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, **Sprenkle P**, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024, 8: 1101-1110. [PMID: 39098389](#), [DOI: 10.1016/j.euo.2024.07.010](#).
 56. Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, **Sprenkle P**. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. [PMID: 39465014](#), [PMCID: PMC11502073](#), [DOI: 10.37349/etat.2024.00269](#).
 57. Kunst N, Long J, Westvold S, **Sprenkle P**, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. [PMID: 39441595](#), [PMCID: PMC11581571](#), [DOI: 10.1001/jamanetworkopen.2024.40591](#).
 58. Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, **Sprenkle P**, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024, 43: 396.e1-396.e7. [PMID: 39438211](#), [DOI: 10.1016/j.urolonc.2024.10.002](#).
 59. Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, **Sprenkle P**, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024, 43: 336.e13-336.e20. [PMID: 39521675](#), [DOI: 10.1016/j.urolonc.2024.10.018](#).
 60. Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Bailey J, Rajwa P, Seibert T, Loeb S, Cooperberg M, Catalona W, **Sprenkle P**, Kim I, Leapman M. Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI. Urologic Oncology Seminars And Original Investigations 2024, 43: 193.e19-193.e26. [PMID: 39706698](#), [DOI: 10.1016/j.urolonc.2024.11.007](#).
 61. Kim I, Leapman M, Kim M, Rahman S, **Sprenkle P**, Renzulli J, Brito J, Hyams E, Kim J, Pareek G, Kim I. Radical prostatectomy is associated with favorable outcomes in patients over 80 years old.

- American Journal Of Clinical And Experimental Urology 2025, 13: 33-42. [PMID: 40124572](#), [PMCID: PMC11928824](#), [DOI: 10.62347/nkgs2301](#).
62. Rabil M, Webb L, Diaz G, Lokeshwar S, Choksi A, **Sprenkle P**. Discrepancies in volume: impact of Artemis segmented magnetic resonance imaging, ultrasound, and ExactVu measurements on prostate specific antigen density and National Comprehensive Cancer Network risk stratification. Central European Journal Of Urology 2025, 78: 1-4. [PMID: 40371423](#), [PMCID: PMC12073516](#), [DOI: 10.5173/ceju.2024.0249](#).
63. Chen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, **Sprenkle P**, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025, 9: 142-149. [PMID: 39924390](#), [PMCID: PMC12332026](#), [DOI: 10.1016/j.euo.2025.01.005](#).
64. Khajir G, Webb L, Lokeshwar S, Diaz G, Anderson T, Choksi A, Zhao J, Leapman M, **Sprenkle P**, Renzulli J. Diagnostic performance of high-resolution micro-ultrasound and conventional ultrasound in fusion biopsy for clinically significant prostate cancer detection. Urologic Oncology Seminars And Original Investigations 2025, 43: 399.e1-399.e8. [PMID: 40121104](#), [DOI: 10.1016/j.urolonc.2025.03.006](#).
65. Sivanesan N, Diaz G, Kandala K, Tan W, **Sprenkle P**. Why prompting matters: achieving clinically accurate and consistent responses with Chat GPT. BJU International 2025, 136: 221-224. [PMID: 40223543](#), [DOI: 10.1111/bju.16738](#).
66. Rabil M, Ghaffar U, Long J, Westvold S, **Sprenkle P**, Kim I, Saperstein L, Kunst N, Wang S, Ma X, Gross C, Leapman M, Karnes R. Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer. JU Open Plus 2025, 3 [DOI: 10.1097/ju9.0000000000000278](#).
67. Smani S, Khan A, Choksi A, Press B, Rahman S, Hayden C, Gardezi M, Jalfon M, Lee J, **Sprenkle P**, Kellner D. Can Anatomical Measurements on Preoperative Pelvic Magnetic Resonance Imaging Predict Postoperative Urinary Incontinence after Holmium Laser Enucleation of the Prostate? Journal Of Endourology 2025, 39: 731-737. [PMID: 40470526](#), [DOI: 10.1089/end.2025.0006](#).
68. Smani S, Wang R, Zhou X, **Sprenkle P**, Kim I, Dinan M, Gross C, Ma X, Leapman M. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology 2025, 205: 145-151. [PMID: 40759400](#), [DOI: 10.1016/j.urology.2025.07.070](#).
69. Sivanesan N, Diaz G, Strachan S, Kandala K, Zhao X, Tan W, Leapman M, **Sprenkle P**. MRI-fusion biopsy era: the role of perineural invasion in low-risk prostate cancer. Current Problems In Cancer 2025, 59: 101251. [PMID: 40946534](#), [DOI: 10.1016/j.currproblcancer.2025.101251](#).
70. Kunst N, Long J, **Sprenkle P**, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Network Open 2025, 8: e2539250. [PMID: 41134573](#), [PMCID: PMC12552925](#), [DOI: 10.1001/jamanetworkopen.2025.39250](#).
71. Sivanesan N, Diaz G, Tan W, Arora S, **Sprenkle P**. Comparative Analysis of Prostate Imaging Reporting and Data System and Prostate Imaging After Focal Ablation Scoring Systems in the Postfocal Therapy Assessment of Clinically Significant Prostate Cancer. Urology Practice 2025, 13: 11-12. [PMID: 40986434](#), [DOI: 10.1097/upj.0000000000000899](#).

72. Zhang A, Sivanesan N, **Sprenkle P**. Pretreatment Predictors of Pathologic Failure at 1 year After Focal Therapy for Localized Prostate Cancer. *European Urology Oncology* 2025, 8: 1710-1711. [PMID: 41136310](#), [DOI: 10.1016/j.euo.2025.10.004](#).
73. Diaz G, Webb L, Lokeshwar S, Choksi A, Leapman M, **Sprenkle P**. Initial pain score during viscous lidocaine instillation and clinical characteristics as predictors of overall pain in fusion prostate biopsy. *Journal Of Biological Methods* 2025, 12: e99010077. [PMID: 41415884](#), [PMCID: PMC12709519](#), [DOI: 10.14440/jbm.0230](#).
74. Diaz G, Sivanesan N, Strachan S, Sohoni N, DuBois J, Zhao X, **Sprenkle P**, Leapman M. Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer. *Urology* 2025, 210: 35-39. [PMID: 41412501](#), [DOI: 10.1016/j.urology.2025.12.004](#).
75. Zhang H, Elsaid N, Nixon T, Dewdney A, Peters D, Weinreb J, **Sprenkle P**, Constable R, Galiana G. Strong-Gradient Diffusion-Weighted Imaging of Prostate Cancer Using an Inside-Out Nonlinear Gradient Coil. *Magnetic Resonance In Medicine* 2026, 95: 2671-2688. [PMID: 41505274](#), [PMCID: PMC12962214](#), [DOI: 10.1002/mrm.70252](#).
76. Leapman M, Long J, Westvold S, Rabil M, **Sprenkle P**, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. *JCO Oncology Practice* 2026, op2500617. [PMID: 41632928](#), [DOI: 10.1200/op-25-00617](#).
77. Ajjawi I, Kim I, Smani S, Palencia P, Diaz G, Lee W, Kim I, **Sprenkle P**, Leapman M. Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer. *Current Urology* 2026, 20: 141-147. [PMID: 41969320](#), [PMCID: PMC13068477](#), [DOI: 10.1097/cu9.0000000000000335](#).
78. Zhang A, Hayden C, Tawfellos G, Rezaeian A, Sivanesan N, Leapman M, **Sprenkle P**. IP26-21 BASELINE MAXIMAL CORE AND TOTAL LENGTH GLEASON PATTERN-4 ASSOCIATED WITH RECURRENCE RISK AFTER PRIMARY FOCAL ABLATION FOR GRADE GROUP 2 PROSTATE CANCER IN A SINGLE INSTITUTION. *Journal Of Urology* 2026, 215: e568. [DOI: 10.1097/01.ju.0001191432.92350.a5.21](#).
79. Ajjawi I, Zhang A, Ward B, **Sprenkle P**, Catalona W, Kim I, Leapman M. IP73-28 ASSOCIATION BETWEEN NEOADJUVANT HORMONAL THERAPY AND CLINICAL-PATHOLOGIC OUTCOMES IN HIGH-RISK PROSTATE CANCER: A CONTEMPORARY NATIONAL ANALYSIS. *Journal Of Urology* 2026, 215: e1478. [DOI: 10.1097/01.ju.0001191728.67566.6d.28](#).
80. Zhang A, Sivanesan N, Rezaeian A, Barreto A, Tawfellos G, Hayden C, **Sprenkle P**. IP26-14 PRE-TREATMENT HIGH-RISK DECIPHER CATEGORY PREDICTS RECURRENCE AFTER PRIMARY FOCAL ABLATION. *Journal Of Urology* 2026, 215: e565. [DOI: 10.1097/01.ju.0001191432.92350.a5.14](#).
81. Zhang A, Tawfellos G, Ferneini I, Forgione L, Honig S, **Sprenkle P**. IP26-28 RECOVERY OF POTENCY AFTER PRIMARY FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A 2-YEAR ANALYSIS BY MODALITY. *Journal Of Urology* 2026, 215: e572. [DOI: 10.1097/01.ju.0001191432.92350.a5.28](#).
82. Ward B, Xi X, Zhang A, Rajwa P, **Sprenkle P**, Kim I, Leapman M. IP37-06 REAL-WORLD SURVEILLANCE PATTERNS FOLLOWING FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A NATIONAL CLAIMS ANALYSIS. *Journal Of Urology* 2026, 215: e776. [DOI: 10.1097/01.ju.0001191504.60654.49.06](#).

83. Zhang A, Tawfellos G, Barreto A, Sivanesan N, Hayden C, **Sprenkle P**. IP37-09 PRE-SALVAGE PSMA PET/CT UTILIZATION AND PROGNOSTIC VALUE IN A CONTEMPORARY SALVAGE COHORT. Journal Of Urology 2026, 215: e778. [DOI: 10.1097/01.ju.0001191504.60654.49.09](https://doi.org/10.1097/01.ju.0001191504.60654.49.09).
84. Barreto A, Zhang A, **Sprenkle P**. IP43-22 VARIATION IN CANCER DETECTION ACROSS UROLOGISTS PERFORMING MRI-TARGETED PROSTATE BIOPSIES USING EXACTVU MICRO-ULTRASOUND. Journal Of Urology 2026, 215: e894. [DOI: 10.1097/01.ju.0001191540.85098.f9.22](https://doi.org/10.1097/01.ju.0001191540.85098.f9.22).

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. **Sprenkle PC**, Fisch H. Pathologic effects of testosterone deprivation. Current Opinion In Urology 2007, 17: 424-430. [PMID: 17921778](https://pubmed.ncbi.nlm.nih.gov/17921778/), [DOI: 10.1097/mou.0b013e3282f0ebef](https://doi.org/10.1097/mou.0b013e3282f0ebef).
2. **Sprenkle P**, Russo P. Molecular markers for ischemia, do we have something better than creatinine and glomerular filtration rate? Archivos Españoles De Urología 2013, 66: 99-114. [PMID: 23406805](https://pubmed.ncbi.nlm.nih.gov/23406805/).
3. Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, **Sprenkle P**, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal Of Urology 2015, 194: 626-634. [PMID: 25849602](https://pubmed.ncbi.nlm.nih.gov/25849602/), [PMCID: PMC4551510](https://pubmed.ncbi.nlm.nih.gov/PMC4551510/), [DOI: 10.1016/j.juro.2015.01.126](https://doi.org/10.1016/j.juro.2015.01.126).
4. Syed JS, Javier-Desloges J, Tatzel S, Bhagat A, Nguyen KA, Hwang K, Kim S, **Sprenkle PC**. Current Management Strategy for Active Surveillance in Prostate Cancer. Current Oncology Reports 2017, 19: 11. [PMID: 28220449](https://pubmed.ncbi.nlm.nih.gov/28220449/), [DOI: 10.1007/s11912-017-0569-6](https://doi.org/10.1007/s11912-017-0569-6).
5. Rajwa P, **Sprenkle PC**, Leapman MS. When and How Should Active Surveillance for Prostate Cancer be De-Escalated? European Urology Focus 2020, 7: 297-300. [PMID: 32019719](https://pubmed.ncbi.nlm.nih.gov/32019719/), [PMCID: PMC7394715](https://pubmed.ncbi.nlm.nih.gov/PMC7394715/), [DOI: 10.1016/j.euf.2020.01.001](https://doi.org/10.1016/j.euf.2020.01.001).
6. Rajwa P, Mori K, Huebner NA, Martin DT, **Sprenkle PC**, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. [PMID: 33904755](https://pubmed.ncbi.nlm.nih.gov/33904755/), [DOI: 10.1097/ju.0000000000001821](https://doi.org/10.1097/ju.0000000000001821).
7. Lokeshwar SD, Syed JS, Segal D, Rahman SN, **Sprenkle PC**. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. Current Oncology Reports 2022, 24: 249-256. [PMID: 35080739](https://pubmed.ncbi.nlm.nih.gov/35080739/), [DOI: 10.1007/s11912-021-01180-1](https://doi.org/10.1007/s11912-021-01180-1).
8. Masoom SN, Sundaram KM, Ghanouni P, Fütterer J, Oto A, Ayyagari R, **Sprenkle P**, Weinreb J, Arora S. Real-Time MRI-Guided Prostate Interventions. Cancers 2022, 14: 1860. [PMID: 35454773](https://pubmed.ncbi.nlm.nih.gov/35454773/), [PMCID: PMC9030365](https://pubmed.ncbi.nlm.nih.gov/PMC9030365/), [DOI: 10.3390/cancers14081860](https://doi.org/10.3390/cancers14081860).
9. Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, **Sprenkle P**. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. [PMID: 38896314](https://pubmed.ncbi.nlm.nih.gov/38896314/), [DOI: 10.1007/s11934-024-01220-w](https://doi.org/10.1007/s11934-024-01220-w).
10. Sundaresan V, Smani S, Rajwa P, Renzulli J, **Sprenkle P**, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024, 43: 41-48. [PMID: 39019723](https://pubmed.ncbi.nlm.nih.gov/39019723/), [DOI: 10.1016/j.urolonc.2024.06.003](https://doi.org/10.1016/j.urolonc.2024.06.003).

11. Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, **Sprenkle P**, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. [PMID: 39280242](#), [PMCID: PMC11390291](#), [DOI: 10.37349/etat.2024.00259](#).
12. Rahman S, Kim H, Webb L, Diaz G, Leapman M, **Sprenkle P**, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. [PMID: 39697737](#), [PMCID: PMC11651831](#), [DOI: 10.21037/tcr-24-245](#).
13. Jalilianhasanpour R, Arora S, Mansoori B, Raman S, Greenwood B, **Sprenkle P**, Schade G, Camacho M, Hosseini N, Westphalen A. MRI after focal therapy for prostate cancer: what radiologists must know? Abdominal Radiology 2024, 50: 2201-2220. [PMID: 39542951](#), [DOI: 10.1007/s00261-024-04670-5](#).
14. Sivanesan N, Diaz G, **Sprenkle P**. Tissue-based gene expression testing in localized prostate cancer. Current Opinion In Urology 2025, 35: 432-438. [PMID: 40314067](#), [DOI: 10.1097/mou.0000000000001289](#).
15. Smani S, Sohoni N, Mischczyk M, Fazekas T, Rajwa P, Grimshaw A, Sundaresan V, Lokeshwar S, Weinreb J, **Sprenkle P**, Cooperberg M, Seibert T, Shariat S, Catalona W, Leapman M. Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis. World Journal Of Urology 2026, 44: 169. [PMID: 41691567](#), [DOI: 10.1007/s00345-026-06278-4](#).
16. Ajjawi I, **Sprenkle P**, Renzulli J, Leapman M. Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches. Urologic Clinics Of North America 2026, 53: 193-203. [PMID: 41986015](#), [DOI: 10.1016/j.ucl.2026.02.002](#).

Chapters

1. Syed J, **Sprenkle P**. Benign and Malignant Diseases of the Prostate. 2019, 1-32. [DOI: 10.1007/978-3-319-20317-1_79-1](#).

Commentaries, Editorials and Letters

1. Cornfeld D, **Sprenkle P**. Multiparametric MRI: standardizations needed. Oncology 2013, 27: 277,280. [PMID: 23781691](#).
2. Syed JS, Lu A, Nguyen KA, **Sprenkle PC**, Weinreb JC. Author Reply. Urology 2017, 105: 122. [PMID: 28449978](#), [DOI: 10.1016/j.urology.2017.01.050](#).
3. **Sprenkle P**. Editorial Comment. Journal Of Urology 2026, 101097ju0000000000005105. [PMID: 42125981](#), [DOI: 10.1097/ju.0000000000005105](#).